Paul Tudor Jones’s Jazz Pharmaceuticals JAZZ Stock Holding History

Paul Tudor Jones’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,500	Closed	-$255K	–	3968
2025 Q4	$255K	Buy	+1,500	New	+$230K	﹤0.01%	3146

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Paul Tudor Jones's JAZZ Position: Q1 2026 in Review

Paul Tudor Jones sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 29,725 shares — an estimated $5.05M sold.

Paul Tudor Jones first reported a position in JAZZ in Q2 2013 and held it in 36 quarters. The position peaked at $7.34M in Q4 2019. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Paul Tudor Jones reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Paul Tudor Jones sold 29,725 Jazz Pharmaceuticals shares in Q1 2026, an estimated $5.05M.
Paul Tudor Jones first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 36 quarters.
Paul Tudor Jones's Jazz Pharmaceuticals position peaked at $7.34M in Q4 2019.
573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.